Biosimilars: FDA Finalizes Supplement Classification Guidance

Ensuring regulatory compliance and quality control through accredited lab testing services in Irvine, CA

FDA’s Final Supplement Classification Guidance for Biosimilars

In September 2025, the U.S. Food and Drug Administration (FDA) finalized new guidance clarifying the classification of biosimilars as dietary supplements under certain regulatory frameworks. This step aims to streamline the regulatory landscape for biosimilar products while maintaining rigorous safety and efficacy standards. The guidance specifies supplemental submission types to align product classification and optimize the regulatory review process. (RAPS, 2025)

This classification update impacts manufacturers and labs handling dietary supplements, including biosimilar-based products that demonstrate biological equivalence to previously approved agents.

Qalitex: Your FDA-Compliant Testing Partner in Southern California

Qalitex, located in Irvine, California, is an ISO 17025–accredited testing laboratory specializing in microbiology and analytical chemistry services. As the FDA finalizes biosimilar supplement guidelines, Qalitex offers comprehensive compliance-focused lab testing for biosimilar dietary supplements and related consumer products.

Our expertise includes but is not limited to:

• Microbiology testing to ensure product safety

• Analytical chemistry lab testing for ingredient verification

• Heavy metal analysis specifically tuned for supplements

• Shelf-life and stability studies, ensuring consistent quality over time

• Method development and validation, supporting FDA compliant submissions

• Amazon-compliance testing to support e-commerce sales channels

By partnering with Qalitex, regulated biosimilar supplement brands in Southern California and nationwide gain a one-stop quality-control partner dedicated to regulatory compliance lab services.

Accreditation & Compliance: Meeting FDA and Industry Standards

Qalitex’s ISO 17025 accreditation validates our laboratory’s competence in conducting reliable and accurate testing on biosimilar supplements and products. We also implement USP and AOAC validated methods to align with FDA expectations.

Our services support key regulatory requirements through:

• FDA compliant product testing to ensure market-ready biosimilar supplements

• Certificate of Analysis (CoA testing) for traceable quality assurance

• Robust documentation supporting FDA submissions tied to the new supplement classification guidance

Core Laboratory Services for Biosimilar Supplements

To meet the specific demands of biosimilar dietary supplements under the FDA’s new framework, Qalitex provides a diverse service menu that encompasses:

• Microbiology testing services to detect impurities and contamination risks

• Analytical chemistry lab testing for assay, potency, and ingredient identity

• Heavy metal analysis for supplements to ensure safety from toxic elements

• Shelf-life and stability studies to characterize product durability and expiration

• Method development and validation for customized analytical approaches supporting biosimilar product claims

These services collectively help biosimilar manufacturers meet regulatory expectations while assuring consumers of product quality and reliability.

Why Southern California Biosimilar Brands Choose Qalitex

With biosimilars becoming increasingly relevant in the dietary supplement sector amid FDA’s updated guidance, brands in Southern California trust Qalitex for localized, fast, and accurate laboratory testing. Our strategically located lab in Irvine offers prompt turnaround times and personalized support, making it easier for manufacturers to comply with emerging regulatory classifications.

Whether you are launching a new biosimilar or navigating supplemental product documentation, Qalitex’s suite of accredited testing services is designed to facilitate FDA compliance, consumer safety, and market success.

What Our Lab Sees

Over seventeen years running supplement testing at Qalitex, we have watched regulatory landscapes shift and manufacturers scramble to adapt. The FDA’s finalized biosimilar supplement classification guidance is no different—it creates clarity, but it also creates new demands for data.

In our lab, biosimilar-based supplements present distinct analytical challenges. Unlike traditional botanical or vitamin formulations, biosimilar ingredients often require specialized analytical chemistry testing to confirm identity and purity. We routinely see manufacturers underestimate how much method development and validation is needed when moving a biosimilar into a supplement format. Matrix effects, excipient interactions, and stability under typical supplement storage conditions all require empirical data—data that third-party labs like ours must generate under ISO 17025 accredited conditions for regulatory acceptance.

From our testing volume over the past two years, roughly 12–15% of biosimilar-containing samples submitted for identity or potency testing have required method refinement before we could report results. This is higher than our average for conventional supplements, where compendial methods cover most scenarios. Brands that engage us early in product development—before formulation lock—tend to avoid costly rework and faster time-to-market. Our method development and validation team has developed protocols specifically for biosimilar matrices, which reduces turnaround and supports FDA-ready documentation.

We also observe that heavy metal and microbiological risks for biosimilar supplements can differ from botanical products. Fermentation-derived ingredients, for example, may introduce different bioburden profiles than plant extracts. Our microbiology testing and heavy metal analysis protocols are adapted for these matrices, and we document any matrix-specific considerations in our Certificate of Analysis reports—critical for brands navigating the new classification framework.

Frequently Asked Questions (FAQs)

What is the FDA’s supplement classification guidance for biosimilars? The FDA’s guidance finalizes how biosimilar biological products are classified as dietary supplements when they meet specific criteria, streamlining regulatory oversight and submissions. How does FDA classification of biosimilars as supplements affect product testing requirements? Biosimilar classification as supplements heightens the need for validated microbiology, chemistry, and stability testing to meet dietary supplement regulatory standards. Why choose an ISO 17025 accredited testing laboratory like Qalitex for biosimilar supplements? ISO 17025 accreditation ensures testing accuracy, repeatability, and regulatory acceptance essential for FDA compliance and market authorization. What core lab services does Qalitex offer to support biosimilar supplement compliance? Qalitex provides microbiology testing, analytical chemistry, heavy metal analysis, shelf-life stability studies, and method development/validation tailored for biosimilar and supplement products. How can Qalitex help with FDA-compliant product testing in light of the updated biosimilar supplement classification? Qalitex’s FDA compliant product testing aligns laboratory results with current regulatory requirements, supporting documentation necessary for biosimilar supplement approval and quality assurance. What is involved in the Certificate of Analysis testing for biosimilar supplements at Qalitex? Certificate of Analysis testing confirms product identity, purity, potency, and safety through accredited laboratory evaluation, essential for FDA regulatory and consumer transparency. Where is Qalitex located and how does geographic proximity benefit Southern California biosimilar manufacturers? Qalitex is located in Irvine, California, providing Southern California biosimilar manufacturers fast access to accredited testing with personalized support and quick turnaround times.

How does the FDA classify biosimilars as dietary supplements? The FDA’s 2025 guidance specifies criteria under which biosimilar biological products may be classified as dietary supplements, streamlining supplemental submissions and product categorization while maintaining safety and efficacy requirements.

What testing does a biosimilar supplement need for FDA compliance? Biosimilar supplements require validated identity, potency, stability, microbiology, and heavy metal testing—typically performed by an ISO 17025 accredited laboratory using USP, AOAC, or validated custom methods that withstand regulatory scrutiny.

Why do biosimilar supplements need specialized analytical methods? Biosimilar ingredients often exist in complex matrices that compendial methods do not fully address. Method development and validation per ICH Q2(R1) ensures accuracy, precision, and regulatory acceptance for novel formulations.

Where can Southern California supplement brands get biosimilar testing? Qalitex, located in Irvine, CA, provides ISO 17025 accredited biosimilar supplement testing including method development, stability studies, microbiology, and heavy metal analysis with fast turnaround for local manufacturers.

Ready to ensure your biosimilar supplements meet FDA’s finalized supplement classification guidance with ISO 17025-accredited accuracy? Get a quote from Qalitex today and partner with Southern California’s trusted microbiology and analytical chemistry laboratory.